Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioXcel TherapeuticsBTAI -1.11%8 Receivables Turnover is 0.92 as of Mar. 2026. GuruFocus rates BTAI with a GF Score™ of 8/100 and a GF Value™ of $0.67 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 949 Drug Manufacturers companies, BioXcel Therapeutics ranks worse than 60.38% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BioXcel Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $0.21 Mil. BioXcel Therapeutics's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.22 Mil.
Hence, BioXcel Therapeutics's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.92.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
BioXcel Therapeutics Receivables Turnover Related Terms
BioXcel Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for BioXcel Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BTAI vs IXHL, SCYX, INIS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioXcel Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioXcel Therapeutics Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioXcel Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where BioXcel Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioXcel Therapeutics (BTAI) has a Receivables Turnover of 0.92 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BioXcel Therapeutics and its competitors. According to the industry distribution chart, BioXcel Therapeutics ranks #573 out of 949 companies in the Drug Manufacturers industry, placing it in the top 60.4%.
Is BioXcel Therapeutics' Receivables Turnover too high?
BioXcel Therapeutics' current Receivables Turnover is 0.92. The Drug Manufacturers industry median Receivables Turnover is 5.07. BioXcel Therapeutics' value of 0.92 is 81.9% below this industry median. Based on the distribution chart, BioXcel Therapeutics ranks #573 out of 949 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, BioXcel Therapeutics has a GF Score™ of 8/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioXcel Therapeutics' Receivables Turnover compare to IXHL and SCYX?
According to the Drug Manufacturers industry distribution chart, BioXcel Therapeutics ranks #573 out of 949 companies for Receivables Turnover. This places BioXcel Therapeutics in the lower half of its industry. The industry median Receivables Turnover is 5.07. BioXcel Therapeutics' value of 0.92 is 81.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioXcel Therapeutics's current Receivables Turnover of 0.92 is 81.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BioXcel Therapeutics and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioXcel Therapeutics's current Receivables Turnover is 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (BTAI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.67, compared to a current price of $0.87 — trading 29.9% above its estimated fair value. The current Receivables Turnover is 0.92 and 81.9% below the Drug Manufacturers industry median of 5.07. BioXcel Therapeutics' overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For BioXcel Therapeutics (BTAI), the current Receivables Turnover is 0.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioXcel Therapeutics (BTAI) Overvalued in 2026?
Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be overvalued.
The current stock price of $0.87 is trading 29.9% above its estimated GF Value™ of $0.67.
GuruFocus considers BioXcel Therapeutics to be Significantly Overvalued.
Key valuation signals for BTAI:
Receivables Turnover: 0.92
GF Value™: $0.67 vs. price of $0.87 (29.9% above fair value)
Industry Position: 81.9% below the Drug Manufacturers median (#573 of 949)
No single metric tells the full story. See the BTAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
8GF Score
Get the complete analysis for BTAI
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTAI has been successfully added to your 
